36 results
Page 2 of 2
8-K
EX-99.1
l52eqy3txe75mz
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
6-K
EX-99.1
i3pcld aomw
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
dowhhxy
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
hlot9jti1za
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
424B2
put vmzgpn4
24 Jan 20
Prospectus for primary offering
7:24am
424B5
i2vdt
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
r02ou
3 Sep 19
Current report (foreign)
7:40am
6-K
EX-99.1
z7mw0d
11 Jun 19
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
7:00am
6-K
EX-99.1
s2gjevtjthpf3zhw88cv
7 Mar 19
Zai Lab Announces Financial Results and Corporate Update for Full Year 2018
7:36am
6-K
EX-99.1
h9zizmj
30 Nov 18
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing development
6:06am
20-F
EX-4.11
o1u411h6e1k3
30 Apr 18
Annual report (foreign)
9:07am
20-F
ci04llwdqhtsf upe01
30 Apr 18
Annual report (foreign)
9:07am
6-K
EX-99.1
kb6o2ce
25 Apr 18
Global Strategic Development Collaboration for ETX2514
12:00am